• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1p/19q共缺失状态对世界卫生组织II级胶质瘤切除范围的影响:来自国家癌症登记处的见解

Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.

作者信息

Lu Victor M, Alvi Mohammed Ali, Bydon Mohamad, Quinones-Hinojosa Alfredo, Chaichana Kaisorn L

机构信息

Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.

Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.

出版信息

Clin Neurol Neurosurg. 2019 Jul;182:32-36. doi: 10.1016/j.clineuro.2019.04.027. Epub 2019 Apr 30.

DOI:10.1016/j.clineuro.2019.04.027
PMID:31063969
Abstract

OBJECTIVE

Traditionally, extent of resection (EOR) has been seen as a surgical parameter that can predict survival outcomes of surgically managed WHO grade II gliomas. The aim of this study was to evaluate if such an influence was potentially affected by 1p/19q codeletion status based on a national cancer registry.

PATIENT AND METHODS

All adults diagnosed with grade II gliomas between the years 2004 to 2014 were queried from the National Cancer Database (NCDB). The population was then divided based on 1p/19q codeletion status, and then Kaplan-Meier, univariate and multivariate Cox regression analyses were utilized to evaluate the prognostic effect of EOR.

RESULTS

In total, 1,498 grade II gliomas satisfied inclusion for analysis, with the 1p/19q non-codeleted in 705 (47%) cases, and codeletion in 793 (53%) cases. When the cohort was divided based on codeletion status, Kaplan-Meier modelling and univariate regression analyses indicated that gross total resection (GTR) was significantly associated with greater 5-overall survival (OS) in both 1p/19q non-codeleted and codeletion groups. Upon multivariate analysis which incorporated adjuvant therapy status, the significance of GTR was only retained in the 1p/19q non-codeletion group after post-hoc adjustment.

CONCLUSION

Our findings indicate that the survival impact of GTR in grade II gliomas may be affected by 1p/19q codeletion status within the first five years after surgery based on overall survival. Therefore, molecular diagnostics have potential clinical application in surgery outcomes, and validation of the reported findings will assist in surgical planning if such an association can be thoroughly established.

摘要

目的

传统上,切除范围(EOR)被视为一个手术参数,可预测接受手术治疗的世界卫生组织二级胶质瘤的生存结果。本研究的目的是基于国家癌症登记处评估这种影响是否可能受1p/19q共缺失状态的影响。

患者与方法

从国家癌症数据库(NCDB)中查询2004年至2014年间所有诊断为二级胶质瘤的成年人。然后根据1p/19q共缺失状态对人群进行划分,接着采用Kaplan-Meier法、单因素和多因素Cox回归分析来评估EOR的预后效果。

结果

共有1498例二级胶质瘤符合纳入分析标准,其中705例(47%)为1p/19q非共缺失,793例(53%)为共缺失。当根据共缺失状态对队列进行划分时,Kaplan-Meier建模和单因素回归分析表明,在1p/19q非共缺失组和共缺失组中,大体全切(GTR)均与更好的5年总生存期(OS)显著相关。在纳入辅助治疗状态的多因素分析中,经过事后调整后,GTR的显著性仅在1p/19q非共缺失组中得以保留。

结论

我们的研究结果表明,基于总生存期,GTR对二级胶质瘤生存的影响可能在术后头五年内受1p/19q共缺失状态的影响。因此,分子诊断在手术结果方面具有潜在的临床应用价值,如果这种关联能够得到充分确立,对所报告结果的验证将有助于手术规划。

相似文献

1
Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.1p/19q共缺失状态对世界卫生组织II级胶质瘤切除范围的影响:来自国家癌症登记处的见解
Clin Neurol Neurosurg. 2019 Jul;182:32-36. doi: 10.1016/j.clineuro.2019.04.027. Epub 2019 Apr 30.
2
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.TERT 启动子突变与 1p/19q 状态无关,对 IDH1/2 突变的成人弥漫性胶质瘤具有有利的预后。
Acta Neuropathol Commun. 2020 Nov 23;8(1):201. doi: 10.1186/s40478-020-01078-2.
3
Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.1p19q 缺失型胶质瘤的切除程度、分子特征与生存
J Neurosurg. 2020 May 8;134(5):1357-1367. doi: 10.3171/2020.2.JNS192767. Print 2021 May 1.
4
Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.IDH 1/2 突变且无 1p/19q 共缺失的 WHO Ⅲ级胶质瘤患者行全切除的影响
J Neurooncol. 2016 Sep;129(3):505-514. doi: 10.1007/s11060-016-2201-2. Epub 2016 Jul 11.
5
Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis.1p/19q 缺失在弥漫性低级别胶质瘤肿瘤预后中的作用。
Anticancer Res. 2023 Jun;43(6):2659-2670. doi: 10.21873/anticanres.16432.
6
Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of -Mutation and 1p/19q-Codeletion Status in World Health Organization Grade II Gliomas.弥散张量成像全肿瘤直方图和纹理分析评估世界卫生组织 II 级胶质瘤的 - 突变和 1p/19q 缺失状态。
AJNR Am J Neuroradiol. 2018 Apr;39(4):693-698. doi: 10.3174/ajnr.A5569. Epub 2018 Mar 8.
7
Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.异柠檬酸脱氢酶(IDH)突变、1p/19q 缺失及磷酸酶和张力蛋白同源物(PTEN)缺失分析可明确临床低级别弥漫性胶质瘤的预后。
Neuro Oncol. 2014 Jul;16(7):914-23. doi: 10.1093/neuonc/not299.
8
MRI and CT Identify Isocitrate Dehydrogenase -Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization.MRI 和 CT 可识别异柠檬酸脱氢酶突变型低级别胶质瘤,这些肿瘤通过荧光原位杂交被错误分类为 1p/19q 缺失状态。
Radiology. 2020 Jan;294(1):160-167. doi: 10.1148/radiol.2019191140. Epub 2019 Nov 12.
9
RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.基于 RNA 编辑的弥漫性神经胶质瘤分类:预测异柠檬酸脱氢酶突变和染色体 1p/19q 联合缺失。
BMC Bioinformatics. 2019 Dec 24;20(Suppl 19):659. doi: 10.1186/s12859-019-3236-0.
10
MRI features predict survival and molecular markers in diffuse lower-grade gliomas.磁共振成像特征可预测弥漫性低级别胶质瘤的生存率及分子标志物。
Neuro Oncol. 2017 Jun 1;19(6):862-870. doi: 10.1093/neuonc/now256.

引用本文的文献

1
Multi-center real-world data-driven web calculator for predicting outcomes in IDH-mutant gliomas: Integrating molecular subtypes and treatment modalities.用于预测异柠檬酸脱氢酶(IDH)突变型胶质瘤预后的多中心真实世界数据驱动型网络计算器:整合分子亚型和治疗方式
Neurooncol Adv. 2024 Dec 16;7(1):vdae221. doi: 10.1093/noajnl/vdae221. eCollection 2025 Jan-Dec.
2
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of surgery in the management of patients with diffuse low grade glioma: update.神经外科医师协会关于手术在弥漫性低级别胶质瘤患者管理中作用的系统评价及循证指南:更新版
J Neurooncol. 2025 Mar;172(1):99-152. doi: 10.1007/s11060-024-04871-4. Epub 2025 Jan 13.
3
Long-term outcomes of CNS WHO grade 2 oligodendroglioma in adult patients: a single-institution experience.
成年患者中枢神经系统WHO 2级少突胶质细胞瘤的长期预后:单机构经验
Discov Oncol. 2024 Jul 6;15(1):268. doi: 10.1007/s12672-024-01136-4.
4
Identifying IDH-mutant and 1p/19q noncodeleted astrocytomas from nonenhancing gliomas: Manual recognition followed by artificial intelligence recognition.从非强化型胶质瘤中识别异柠檬酸脱氢酶(IDH)突变型和1p/19q未缺失型星形细胞瘤:先人工识别,再人工智能识别。
Neurooncol Adv. 2024 Feb 1;6(1):vdae013. doi: 10.1093/noajnl/vdae013. eCollection 2024 Jan-Dec.
5
Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.重新思考强化和非强化肿瘤的切除范围:对2021年世界卫生组织分类中成人型弥漫性胶质瘤生存的不同影响
Eur Radiol. 2024 Feb;34(2):1376-1387. doi: 10.1007/s00330-023-10125-0. Epub 2023 Aug 23.
6
Long-term follow up of patients with WHO grade 2 oligodendroglioma.WHO 分级 2 级少突胶质细胞瘤患者的长期随访。
J Neurooncol. 2023 Aug;164(1):65-74. doi: 10.1007/s11060-023-04368-6. Epub 2023 Aug 21.
7
The current state of glioma data registries.胶质瘤数据登记处的现状。
Neurooncol Adv. 2022 Jun 24;4(1):vdac099. doi: 10.1093/noajnl/vdac099. eCollection 2022 Jan-Dec.
8
Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better.11年间成人低级别胶质瘤的癫痫发作结局与生存情况:活得更长且更好。
Neurooncol Pract. 2020 Mar;7(2):196-201. doi: 10.1093/nop/npz056. Epub 2019 Nov 21.